Document is current

Any future updates will be listed below

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes

Crossref DOI link: https://doi.org/10.1007/s13300-018-0445-x

Published Online: 2018-05-25

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark